#Switzerland #Basel #CordenPharma #Dr. Michael Quirmbach #Dr. Jean-Luc Herbeaux

CordenPharma Announces Leadership Transition

CordenPharma, a prominent pharmaceutical CDMO, has made a pivotal announcement regarding its leadership. Effective October 1, 2026, Dr. Jean-Luc Herbeaux will take the helm as CEO, succeeding Dr. Michael Quirmbach. This strategic transition comes at a time when the company is poised for the next phase of growth following 12 years of substantial transformation under Quirmbach's guidance.

Changes in Leadership

Dr. Michael Quirmbach, who has been at the forefront of CordenPharma's operations since 2019, has played a significant role in shaping the company into a globally recognized CDMO. He will shift roles to continue contributing to the firm as a board member and senior advisor, where he will offer his extensive insights and expertise to support, steer, and guide the company further. This planned transition is a testament to the strong leadership framework that has been established over the years.

About Dr. Jean-Luc Herbeaux

Dr. Herbeaux joins CordenPharma with a wealth of experience from Hovione, where he served as CEO for more than four years. His background also includes key executive roles at Evonik, a leader in specialty chemicals and sustainable materials. At CordenPharma, he will focus on executing the long-term strategic plans of the organization, emphasizing growth, operational excellence, and customer satisfaction while continuing to expand the global footprint of the company.

The timing of Dr. Herbeaux's appointment is critical, as CordenPharma is entering a new phase of development. Recent expansions, including the acquisition of peptide CDMO AmbioPharm, underscore the company’s commitment to enhancing its development and production capabilities across its network. Currently, CordenPharma employs around 3,500 professionals and maintains a robust production network in the USA, Europe, and Asia.

Achievements Under Dr. Quirmbach

Dr. Quirmbach's tenure at CordenPharma was marked by impressive figures, with the company’s annual revenue skyrocketing from €245 million to over €1 billion over twelve years. His direction helped solidify CordenPharma’s position as a global leader in the CDMO space. Judith Charpentier, a co-leader at Flagship, commended his contributions, expressing gratitude for his leadership and collaboration in building the organization to where it stands today.

Future Prospects

As Dr. Herbeaux prepares to guide CordenPharma forward, he remains respectful of the legacy that Dr. Quirmbach has built. He acknowledged the exciting opportunities ahead and emphasized the importance of deepening relationships with customers and strengthening the operational capabilities that are critical for developing and producing lifesaving medications worldwide.

In his transition, Dr. Quirmbach expressed pride in the accomplishments during his leadership while looking forward to supporting the company’s next steps as a board member and senior advisor.

This leadership change signals a robust commitment to ongoing innovation and excellence within CordenPharma as it aims to expand further and respond to the evolving needs of the pharmaceutical industry.

Conclusion

CordenPharma’s appointment of Dr. Jean-Luc Herbeaux heralds a new chapter for the firm, with aspirations to sustain and build upon its extensive growth trajectory under new management. As the company looks to the future, the integration of new leadership promises to foster continued commitment to operational excellence and customer satisfaction while navigating through the next phases of its corporate journey, which continues to be driven by strategic partnerships and cutting-edge innovation in the pharmaceutical landscape.